The global demand for advanced therapeutic peptides and targeted drug delivery systems has reached unprecedented heights. Looking back at CPHI & PMEC China 2025, Yaosen Peptide established a strong foundation for this year’s ongoing technological leaps by showcasing our highly competitive, proprietary peptide modification platform.
During the three-day exhibition, our technical team engaged in deep academic and commercial dialogues with premium international pharmaceutical enterprises. A key highlight at our booth was our advanced Fluorescent Labeling service. We demonstrated how our precise conjugation of dyes such as FITC, FAM, TAMRA, and Cy3/Cy5/Cy7 maintains optimal stability and bioactivity, providing indispensable tools for bioimaging, cellular uptake studies, and diagnostic assays.
Furthermore, our expertise in complex peptide modifications was a major crowd-puller. Global researchers widely acclaimed our robust capabilities in:
-
- Terminal Modifications: High-efficiency N-terminal acetylation and C-terminal amidation to prevent enzymatic degradation.
-
- Side-Chain Modifications: Precision phosphorylation (Ser, Thr, Tyr) and methylation for signal transduction research.
-
- Structural Mimics & Stabilization: Disulfide bond formation and advanced cyclization (mono-cyclic, multi-cyclic) to secure rigid conformations and enhance in vivo half-life.
Every batch delivered by Yaosen Peptide undergoes rigorous RP-HPLC purification and Mass Spectrometry (MS) validation, ensuring guaranteed purity levels up to 98% or higher with comprehensive analytical documentation (HPLC chromatogram and MS spectra).
Building on the fruitful partnerships and high-volume orders initiated at CPHI 2025, Yaosen Peptide is scaling up its production lines this year in 2026 to support your clinical trials from milligram pilot studies to kilogram-level commercial manufacturing. We extend our sincere gratitude to all collaborators who visited us last year, and we look forward to driving more biomedical breakthroughs together throughout 2026.